Baseline characteristics and age-related macular degeneration in participants of the “ASPirin in Reducing Events in the Elderly” (ASPREE)-AMD trial

摘要

PurposeTo describe the baseline participant characteristics in the ASPREE-AMD study, investigating the effect of aspirin on AMD incidence and progression.MethodsAustralian participants from the ASPirin in Reducing Events in the Elderly (ASPREE) trial, randomized to 100?mg aspirin daily or placebo, had non-mydriatic, digital color fundus images graded according to the Beckman AMD classification. Associations with AMD were determined for baseline characteristics and genetic risk variants.ResultsASPREE-AMD sub-study enrolled 4993 participants with gradable macular images. Median age was 73.4 years (IQR, 71.5, 76.6), 52% were female, 10% had diabetes mellitus, 73% had hypertension, and 44% were former/current smokers. Early, intermediate and late AMD (detected in 20.6%, 16.1%, 1.1%, respectively), significantly associated with age, were also associated with increasing HDL levels: OR?=?1.52 (95%CI, 1.26, 1.84), OR?=?1.43 (1.17, 1.77) and OR?=?1.96 (1.02, 3.76), respectively. Female sex was associated with early [OR?=?1.37 (1.16, 1.62)], and intermediate [OR?=?1.35 (1.12, 1.63)] AMD, as was previous regular use of aspirin, with OR?=?1.46 (1.11, 1.92) and OR?=?1.37 (1.01, 1.85), respectively. Current smoking had increased odds for late AMD, OR?=?4.02 (1.42, 11.36). Genetic risk variant rs3750846 (ARMS2/HTRA1) was associated with each AMD stage (p?